Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Morris

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Case Reports in Hematology|February 20, 2015
Long complete remission achieved with the combination therapy of Cisplatin and gemcitabine in a patient with aggressive natural killer cell leukemiaJustin LaPorte, Lawrence Morris, John Koepke
Blood Reviews|April 21, 2016
Extramedullary acute myelogenous leukemiaMelhem Solh, Scott Solomon, Lawrence Morris, et al.
American Journal of Hematology|September 26, 2003
Infliximab for steroid-refractory acute GVHD: a case seriesDavid A Jacobsohn, Jason Hallick, Viki Anders, et al.
Leukemia Research|July 21, 2007
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disordersJudith E Karp, Francis J Giles, Ivana Gojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumabJudith E Karp, Ivana Gojo, Roberto Pili, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2014
Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapyMindy Leech, Lawrence Morris, Moishe Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemiaSteven D Gore, Ivana Gojo, Mikkael A Sekeres, et al.
American Journal of Hematology|June 2, 2005
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemiaSteven D Gore, B Douglas Smith, Ivana Gojo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 22, 2018
Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 StudyRyan Spellecy, Sergey Tarima, Ellen Denzen, et al.
Blood|November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaJeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Case Reports in Hematology|February 20, 2015
Long complete remission achieved with the combination therapy of Cisplatin and gemcitabine in a patient with aggressive natural killer cell leukemiaJustin LaPorte, Lawrence Morris, John Koepke
Blood Reviews|April 21, 2016
Extramedullary acute myelogenous leukemiaMelhem Solh, Scott Solomon, Lawrence Morris, et al.
American Journal of Hematology|September 26, 2003
Infliximab for steroid-refractory acute GVHD: a case seriesDavid A Jacobsohn, Jason Hallick, Viki Anders, et al.
Leukemia Research|July 21, 2007
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disordersJudith E Karp, Francis J Giles, Ivana Gojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumabJudith E Karp, Ivana Gojo, Roberto Pili, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2014
Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapyMindy Leech, Lawrence Morris, Moishe Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemiaSteven D Gore, Ivana Gojo, Mikkael A Sekeres, et al.
American Journal of Hematology|June 2, 2005
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemiaSteven D Gore, B Douglas Smith, Ivana Gojo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 22, 2018
Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 StudyRyan Spellecy, Sergey Tarima, Ellen Denzen, et al.
Blood|November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaJeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Pageof 2